
Derek Gilroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8844894/publications.pdf Version: 2024-02-01



DEDEK CILDOV

#	Article	IF	CITATIONS
1	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 14-20.	14.3	4,638
2	Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 2019, 25, 1822-1832.	30.7	2,195
3	Inducible cyclooxygenase may have anti-inflammatory properties. Nature Medicine, 1999, 5, 698-701.	30.7	1,168
4	Possible new role for NF-κB in the resolution of inflammation. Nature Medicine, 2001, 7, 1291-1297.	30.7	971
5	Resolution of in flammation: state of the art, definitions and terms. FASEB Journal, 2007, 21, 325-332.	0.5	949
6	Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nature Reviews Immunology, 2002, 2, 787-795.	22.7	751
7	The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. Journal of Experimental Medicine, 2017, 214, 1913-1923.	8.5	725
8	Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity, 2014, 40, 315-327.	14.3	666
9	Inflammatory Resolution: new opportunities for drug discovery. Nature Reviews Drug Discovery, 2004, 3, 401-416.	46.4	664
10	Resolution of inflammation: a new therapeutic frontier. Nature Reviews Drug Discovery, 2016, 15, 551-567.	46.4	642
11	The resolution of inflammation. Nature Reviews Immunology, 2013, 13, 59-66.	22.7	454
12	Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood, 2008, 112, 4117-4127.	1.4	280
13	Chronic inflammation: a failure of resolution?. International Journal of Experimental Pathology, 2006, 88, 85-94.	1.3	275
14	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. Journal of Immunology, 2009, 183, 2089-2096.	0.8	272
15	Old and new generation lipid mediators in acute inflammation and resolution. Progress in Lipid Research, 2011, 50, 35-51.	11.6	271
16	Transcriptomic analyses of murine resolution-phase macrophages. Blood, 2011, 118, e192-e208.	1.4	253
17	Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nature Medicine, 2014, 20, 518-523.	30.7	240
18	Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood, 2011, 118, 5918-5927.	1.4	236

#	Article	IF	CITATIONS
19	Hematopoietic prostaglandin D ₂ synthase controls the onset and resolution of acute inflammation through PGD ₂ and 15-deoxyſ" ^{12–14} PGJ ₂ . Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20979-20984.	7.1	230
20	A sestrin-dependent Erk–Jnk–p38 MAPK activation complex inhibits immunity during aging. Nature Immunology, 2017, 18, 354-363.	14.5	223
21	15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation. Journal of Experimental Medicine, 2004, 200, 69-78.	8.5	215
22	Cycloâ€oxygenase and nitric oxide synthase isoforms in rat carrageeninâ€induced pleurisy. British Journal of Pharmacology, 1994, 113, 693-698.	5.4	199
23	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. New England Journal of Medicine, 2021, 384, 808-817.	27.0	181
24	A novel role for phospholipase A 2 isoforms in the checkpoint control of acute inflammation. FASEB Journal, 2004, 18, 489-498.	0.5	174
25	Aging immunity may exacerbate COVID-19. Science, 2020, 369, 256-257.	12.6	166
26	Resolution of acute inflammation bridges the gap between innate and adaptive immunity. Blood, 2014, 124, 1748-1764.	1.4	142
27	COX-2 in Inflammation and Resolution. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 199-207.	3.4	141
28	Sestrins induce natural killer function in senescent-like CD8+ T cells. Nature Immunology, 2020, 21, 684-694.	14.5	139
29	Inducible cyclooxygenaseâ€derived 15deoxy Δ 12â€14 PGJ 2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB Journal, 2003, 17, 2269-2271.	0.5	135
30	Different glucocorticoids vary in their genomic and nonâ€genomic mechanism of action in A549 cells. British Journal of Pharmacology, 2002, 135, 511-519.	5.4	131
31	Is Resolution the End of Inflammation?. Trends in Molecular Medicine, 2019, 25, 198-214.	6.7	131
32	Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5179-5184.	7.1	122
33	Resolution of inflammation. International Journal of Immunopharmacology, 2000, 22, 1131-1135.	1.1	121
34	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. European Journal of Pharmacology, 1998, 355, 211-217.	3.5	116
35	New insights into the resolution of inflammation. Seminars in Immunology, 2015, 27, 161-168.	5.6	115
36	Lipid Mediators in Inflammation. Microbiology Spectrum, 2016, 4, .	3.0	115

#	Article	IF	CITATIONS
37	New insights into the role of COX 2 in inflammation. Journal of Molecular Medicine, 2000, 78, 121-129.	3.9	113
38	CYP450-derived oxylipins mediate inflammatory resolution. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3240-9.	7.1	107
39	Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8842-8847.	7.1	106
40	Inflammatory triggers of acute rejection of organ allografts. Immunological Reviews, 2014, 258, 132-144.	6.0	105
41	Macrophage development and polarization in chronic inflammation. Seminars in Immunology, 2015, 27, 257-266.	5.6	97
42	A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties. Journal of Immunology, 2010, 184, 1516-1525.	0.8	96
43	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflammation Research, 1998, 47, 79-85.	4.0	92
44	Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nature Immunology, 2020, 21, 615-625.	14.5	87
45	Selective Suppression of CCAAT/Enhancer-binding Protein Î ² Binding and Cyclooxygenase-2 Promoter Activity by Sodium Salicylate in Quiescent Human Fibroblasts. Journal of Biological Chemistry, 2001, 276, 18897-18904.	3.4	82
46	Colocalization and Interaction of Cyclooxygenase-2 with Caveolin-1 in Human Fibroblasts. Journal of Biological Chemistry, 2001, 276, 34975-34982.	3.4	82
47	Secretory leukocyte protease inhibitor: A pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology, 2014, 59, 1564-1576.	7.3	80
48	Lipid mediators in immune dysfunction after severe inflammation. Trends in Immunology, 2014, 35, 12-21.	6.8	78
49	Lipid mediators in immune regulation and resolution. British Journal of Pharmacology, 2019, 176, 1009-1023.	5.4	74
50	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. PLoS ONE, 2011, 6, e26591.	2.5	71
51	Inflammatory Resolution Triggers a Prolonged Phase of Immune Suppression through COX-1/mPGES-1-Derived Prostaglandin E 2. Cell Reports, 2017, 20, 3162-3175.	6.4	69
52	Nitric Oxide Synthase Inhibitors Have Opposite Effects on Acute Inflammation Depending on Their Route of Administration. Journal of Immunology, 2001, 166, 1169-1177.	0.8	68
53	Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli–driven acute inflammation. JCI Insight, 2018, 3, .	5.0	66
54	Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood, 2008, 111, 4184-4192.	1.4	65

#	Article	IF	CITATIONS
55	Pathways mediating resolution of inflammation: when enough is too much. Journal of Pathology, 2013, 231, 8-20.	4.5	61
56	Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. Biochemical Journal, 2003, 371, 927-935.	3.7	57
57	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity, 2014, 41, 339-340.	14.3	53
58	Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood, 2010, 116, 2950-2959.	1.4	52
59	Potent Antiâ€Inflammatory and Proâ€Resolving Effects of Anabasum in a Human Model of Selfâ€Resolving Acute Inflammation. Clinical Pharmacology and Therapeutics, 2018, 104, 675-686.	4.7	52
60	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
61	Inhibition of NF-κB Activity by a Membrane-Transducing Mutant of lκBα. Journal of Immunology, 2002, 169, 2587-2593.	0.8	50
62	Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 738-747.e7.	4.4	47
63	COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?. Prostaglandins and Other Lipid Mediators, 2000, 62, 33-43.	1.9	45
64	Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Current Opinion in Pharmacology, 2005, 5, 405-411.	3.5	42
65	Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable I?B? repressor. Arthritis and Rheumatism, 2004, 50, 2675-2684.	6.7	41
66	A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis. FEBS Letters, 2010, 584, 3955-3961.	2.8	40
67	New insights into the anti-inflammatory actions of aspirin- induction of nitric oxide through the generation of epi-lipoxins. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 49-54.	1.6	39
68	Eicosanoids and the endogenous control of acute inflammatory resolution. International Journal of Biochemistry and Cell Biology, 2010, 42, 524-528.	2.8	39
69	Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen-specific tissue immunity during human aging. Nature Aging, 2021, 1, 101-113.	11.6	39
70	Inducible CYP2J2 and Its Product 11,12-EET Promotes Bacterial Phagocytosis: A Role for CYP2J2 Deficiency in the Pathogenesis of Crohn's Disease?. PLoS ONE, 2013, 8, e75107.	2.5	37
71	Cell cycleâ€dependent expression of cyclooxygenaseâ€2 in human fibroblasts. FASEB Journal, 2001, 15, 288-290.	0.5	36
72	The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 203-210.	2.2	36

#	Article	IF	CITATIONS
73	The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Inflammation, 1998, 22, 509-519.	3.8	35
74	Pre/pro-B cells generate macrophage populations during homeostasis and inflammation. Proceedings of the United States of America, 2017, 114, E3954-E3963.	7.1	32
75	Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. Biology of Sex Differences, 2015, 6, 27.	4.1	29
76	COX-2 expression and cell cycle progression in human fibroblasts. American Journal of Physiology - Cell Physiology, 2001, 281, C188-C194.	4.6	28
77	Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation. Journal of Visualized Experiments, 2016, , .	0.3	28
78	Characterisation of Leukocytes in a Human Skin Blister Model of Acute Inflammation and Resolution. PLoS ONE, 2014, 9, e89375.	2.5	27
79	Potential Adverse Effects of Cyclooxygenase-2 Inhibition. BioDrugs, 2001, 15, 1-9.	4.6	26
80	New Perspectives on Aspirin and the Endogenous Control of Acute Inflammatory Resolution. Scientific World Journal, The, 2006, 6, 1048-1065.	2.1	25
81	Nonresolving Inflammation in gp91phoxâ^'/â^' Mice, a Model of Human Chronic Granulomatous Disease, Has Lower Adenosine and Cyclic Adenosine 5′-Monophosphate. Journal of Immunology, 2009, 182, 3262-3269.	0.8	25
82	Novel translational model of resolving inflammation triggered by UVâ€killed <i>E. coli</i> . Journal of Pathology: Clinical Research, 2016, 2, 154-165.	3.0	24
83	Purification and characterization of a cyclooxygenase $\hat{\epsilon}\hat{\epsilon}$ and angiogenesis suppressing factor produced by human fibroblasts. FASEB Journal, 2002, 16, 1286-1288.	0.5	23
84	Prolonged immune alteration following resolution of acute inflammation in humans. PLoS ONE, 2017, 12, e0186964.	2.5	23
85	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial. BMJ Open, 2018, 8, e023754.	1.9	22
86	Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1682-H1688.	3.2	21
87	Bile ductâ€ligated mice exhibit multiple phenotypic similarities to acuteÂdecompensation patients despite histological differences. Liver International, 2016, 36, 837-846.	3.9	20
88	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. Clinical Gastroenterology and Hepatology, 2018, 16, 748-755.e6.	4.4	19
89	Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue. International Journal of Obesity, 2008, 32, 1807-1815.	3.4	18
90	Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A ₄ Mimetics (QNX-sLXms). Journal of Medicinal Chemistry, 2021, 64, 9193-9216.	6.4	18

#	Article	IF	CITATIONS
91	Prostaglandin F2α produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology, 2005, 12, 473-476.	3.9	16
92	The Effect of Pro-Inflammatory Conditioning and/or High Glucose on Telomere Shortening of Aging Fibroblasts. PLoS ONE, 2013, 8, e73756.	2.5	16
93	Inducible enzymes with special reference to COX-2 in inflammation and apoptosis. , 1996, , 67-83.		11
94	Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation. Drug News and Perspectives, 2000, 13, 587.	1.5	11
95	Resolution for Sepsis?. Circulation, 2005, 111, 2-4.	1.6	10
96	The resolution of acute inflammation: A â€~tipping point' in the development of chronic inflammatory diseases. , 2008, , 1-18.		10
97	Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins. , 2010, , 153-174.		10
98	Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. Biochemical and Biophysical Research Communications, 2015, 463, 774-780.	2.1	10
99	The endogenous control of acute inflammation – from onset to resolution. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 313-319.	0.5	9
100	Not all eicosanoids are bad. Trends in Pharmacological Sciences, 2006, 27, 609-611.	8.7	8
101	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19. , 2021, 221, 107745.		8
102	Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. British Journal of Clinical Pharmacology, 2022, 88, 680-690.	2.4	8
103	Assessment of Leukocyte Trafficking in Humans using the Cantharidin Blister Model. JRSM Cardiovascular Disease, 2012, 1, 1-5.	0.7	7
104	A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation. PLoS ONE, 2016, 11, e0165502.	2.5	7
105	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial. BMJ Open, 2016, 6, e010132.	1.9	7
106	In Vivo Models to Study Cyclooxygenase Products in Health and Disease: Introduction to Part III. Methods in Molecular Biology, 2010, 644, 181-188.	0.9	7
107	HIF1α Allows Monocytes to Take a Breather during Sepsis. Immunity, 2015, 42, 397-399.	14.3	6
108	Beyond dexamethasone, emerging immunoâ€ŧhrombotic therapies for COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 845-857.	2.4	6

#	Article	IF	CITATIONS
109	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway. JHEP Reports, 2021, 3, 100332.	4.9	6
110	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2006, , 672271.	0.5	4
111	Targeting Lipoxygenases with Care. Chemistry and Biology, 2006, 13, 1121-1122.	6.0	4
112	Regulation of growth and survival of activated T cells by cellâ€ŧransducing inhibitors of Ras. FEBS Letters, 2009, 583, 61-69.	2.8	4
113	Potent antiâ€inflammatory effects of an H ₂ Sâ€releasing naproxen (ATBâ€346) in a human model of inflammation. FASEB Journal, 2021, 35, e21913.	0.5	4
114	Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. International Journal of Immunopharmacology, 1999, 21, 195-203.	1.1	3
115	Inhibition of the diclofenacâ€induced cyclooxygenaseâ€2 activity by paracetamol in cultured macrophages is not related to the intracellular lipid hydroperoxide tone. Fundamental and Clinical Pharmacology, 2011, 25, 186-190.	1.9	3
116	Lipid Mediators in Inflammation. , 2017, , 343-366.		3
117	Resolving inflammation. Nature Reviews Immunology, 2021, 21, 620-621.	22.7	3
118	Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 111, 964-971.	4.7	3
119	Resolution of Acute Inflammation and Wound Healing. , 2010, , 17-27.		2
120	Directed issue: Novel concepts in inflammation. International Journal of Biochemistry and Cell Biology, 2010, 42, 480-481.	2.8	2
121	New insights into inflammatory resolution. Inflammopharmacology, 2001, 9, 125-130.	3.9	1
122	Neutrophil–Endothelial Cell Interactions. , 0, , 141-152.		1
123	FRI-109-Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration. Journal of Hepatology, 2019, 70, e435.	3.7	1
124	The role of the inducible enzymes cyclooxygenase-2, nitric oxide synthase and heme oxygenase in angiogenesis of inflammation. , 1999, , 125-147.		1
125	Nonsteroidal Anti-Inflammatory Drugs. , 0, , 234-243.		0
126	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0, , 282-298.		0

#	Article	IF	CITATIONS
127	Inflammation in Cardiovascular Diseases. , 0, , 317-328.		0
128	Macrophages. , 0, , 96-106.		0
129	Lung. , 0, , 253-258.		0
130	57 SECRETORY LEUKOCYTE PROTEASE INHIBITOR (SLPI) IS A PIVOTAL MEDIATOR OF ANTI-INFLAMMATORY RESPONSES IN ACUTE LIVER FAILURE. Journal of Hepatology, 2013, 58, S26.	3.7	0
131	SP0135â€Mononuclear cells and the reoslution of acute inflammation. Annals of the Rheumatic Diseases, 2013, 71, 33.4-34.	0.9	0
132	O154 PROSTAGLANDIN E2 MEDIATES IMMUNOSUPPRESSION IN ACUTELY DECOMPENSATED CIRRHOSIS. Journal of Hepatology, 2014, 60, S64.	3.7	0
133	P1327 : Attire: albumin to prevent infection in chronic liver failure. Journal of Hepatology, 2015, 62, S853.	3.7	0
134	Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions. Journal of Hepatology, 2017, 66, S390.	3.7	0
135	Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities. Journal of Hepatology, 2017, 66, S390.	3.7	0
136	Exaggerated Onset and Delayed Resolution of Acute Inflammation in Ulcerative Colitis. Gastroenterology, 2017, 152, S996.	1.3	0
137	5-Aminosalicylates Promote Generation of Anti-Inflammatory Hydroxy Fatty Acids that Contribute to Inflammation Resolution in Ulcerative Colitis. Gastroenterology, 2017, 152, S996-S997.	1.3	0
138	227â€Infarct size in a rat model of acute myocardial infarction is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-il-6r monoclonal antibody. Heart, 2017, 103, A146.2-A146.	2.9	0
139	P4940Infarct size in a rat model of STEMI is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-IL6R monoclonal antibody. European Heart Journal, 2017, 38, .	2.2	0
140	OWE-015â€Prostaglandin E2 mediates innate immune suppression in acute-on-chronic liver failure via the EP4 receptor. , 2018, , .		0
141	FRI-112-Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis. Journal of Hepatology, 2019, 70, e436.	3.7	0
142	Dying cell-derived SAM switches off inflammation. Nature Metabolism, 2022, , .	11.9	0